Introduction
Phagocytosis by macrophages1 is essential to metazoan life. Without it, organs would go unmodelled, wounds unmended. Senescent cells would stagnate in the vessels, invading microbes flourish in the tissues. Recent research, however, has focussed more on macrophage secretion than on endocytosis. There is cogent cause for this intense interest in macrophage products. Macrophages in large numbers (1) line submucosae, pulmonary alveoli, juxtaglomerular and other perivascular spaces, bony trabeculae, and renal tubules (2) . They congregate in most subacute or chronic inflammatory reactions, including exudates, granulomas, fatty streaks, and atheromas (3) . In culture, they provide monotypic, monodisperse, differentiating cell populations that react dramatically to soluble and particulate stimuli of mammalian and microbial origin and of physiologic and pharmacologic interest. Their responses include the secretion of some 100 substances, ranging in molecular mass from 32 (superoxide anion) to 440,000 (fibronectin), and in biologic activity from induction ofcell growth to cell death. This rich an array ofproducts has been demonstrated for few if any other cells. Thus, through their abundance, distribution, motility, responsivity, and versatility, macrophages can influence almost every aspect of the immune and inflammatory responses, from acute to delayed hypersensitivity, from the first breach of epithelium to its eventual repair.
Constraints on space confine this review to a catalog with commentary. Worthy topics that cannot be covered include control of secretion at the intercellular, cell surface, and intracellular levels, and the heterogeneity ofsecretion by macrophages of different species, anatomic sources, and states of differentiation.
Multiple macrophage products
Paradoxically, the list of macrophage secretory products (Table  I) has not grown much longer in the last few years, despite continual entries. The explanation is the increased molecular definition of entities previously known only as activities. This has permitted two insights: that a single macrophage product can have diverse activities, and that a single activity can reflect the action ofmany macrophage products. Thus, while earlier reviews (51, 102, 103) listed many activities, Table I can now be restricted mostly to molecules. A few activities are included whose preliminary characterization supports their distinction. A third generalization has also emerged: few ifany ofthe products in Table  I arise solely from macrophages. Evaluation of the importance of macrophages as their source requires consideration of the anatomic and pathophysiologic circumstances pertaining in each instance. These three points are illustrated below.
Multiple activities ofindividual products
The remarkable polypeptide hormones interleukin 1-a and interleukin I-3, and TNF-a or cachectin,2 vividly illustrate this point. Each was discovered in one of the few bioassays which, in retrospect, could distinguish it from the other. Thus, IL-1 (104-106), but not TNF (107), promotes the expression of interleukin 2 receptors and mitogenic response of T cells, while TNF (7), but not IL-1 (Paliadino, M. A., Jr., personal communication) causes hemorrhagic necrosis of certain tumor implants in mice. The purification and cloning (4-11) of these molecules has allowed them to lay claim to a wide range of bioactivities of major importance to the pathogenesis of inflammatory responses, both acute (fever, shock, altered levels ofhormones, coagulopathies, adherence ofleukocytes to endothelium), subacute (tumor cell injury, muscle breakdown, development of humoral and cell-mediated immunity), and chronic (wound healing, fibrosis, erosion of cartilage, remodelling ofbone) (Table  II) . Whether pure IL-I or TNF induces cachexia awaits demonstration. The diversity ofactions ofthese hormones on a single cell type, combined with the numerous types of cells that are their targets, is reminiscent of the action of glucocorticoidswhich IL-I induces (183, 184) and which in turn suppress IL-I release (192) .
Why does the macrophage transcribe at least three different genes (IL-I-a and -,l, TNF-a) encoding potent pleiotropins with largely but incompletely shared functions? We know too little about inflammation to appreciate the implications. Part of the functional overlap may be more apparent than real, since IL-I and TNF can induce each other's release by some cells (107, 118, 139, 156a) , notably macrophages themselves. Thus, some of the actions attributed to one of these monokines may be due to the unsuspected presence of the other. However, in at least one instance where this possibility was considered, IL-I and TNF exerted a shared action independently (139). Even the macrophage secretory products of lowest molecular weight have diverse effects. The reactive oxygen intermediates Interleukin 1-a and 1-fl (collectively, IL-1) (4-6) Tumor necrosis factor-a (cachectin) (TNF) (7-11) Interferons-a (12, 13) Interferon-y (confirmation needed) (14, 15) Platelet-derived growth factor(s) (16, 17) Fibroblast growth factors (18, 19) Fibroblast activating factors (20) Transforming growth factor-f (21) Insulinlike activity (22) Thymosin B4 (23) Erythropoietin (24) Colony-stimulating factor for granulocytes and macrophages (CSF-G/M) (25; but see 25a and 139a)
Colony-stimulating factor for granulocytes (CSF-G) (25a)
Erythroid colony-potentiating factor (26) Factor-inducing monocytopoiesis (27) 3-Endorphin (28) Adrenocorticotrophic hormone (28) Plasmacytoma growth factor (29) Neutrophil-activating factor (30)
Complement (C) components (31-35)
Classical path: Cl, C4, C2, C3, C5 damage a wide variety of cells. At lower concentrations, they elicit noncytotoxic secretory responses, and modify the products of the cells of origin as well as of neighboring cells. The consequences are both pro-and anti-inflammatory (Table III) .
Multiple products with similar activities There are many examples, besides IL-I and TNF, of this phenomenon (Table IV) . As yet, there has been little study of potential interactions among such products (195) . As with IL-1 and TNF, we do not yet appreciate the strengths or subtleties of control that apparent redundancy can afford, such as synergy through affecting a pathway at different points; selectivity through engaging receptors represented differentially on potential targets; or temporal modulation through dissimilar kinetics of product release, product decay, and target cell response.
Multiple cell sources
A few of the products in Table I have not yet been shown to come from cells other than macrophages. Examples are neopterin (95, 96) and the reactive intermediates in the oxidation of nitrogen (101) . This may change when a wider spectrum of cell types is tested. Most of the factors in Table I ilarities to TNF are produced by natural killer cells (120) and some transformed fibroblasts (196) , while IL-1-like factors are released by B cells, natural killer cells, polymorphonuclear leukocytes, endothelial cells, epidermal cells, astroglia, and some hepatomas (197) . Likewise, reactive oxygen intermediates are released not only by macrophages (198) and polymorphonuclear leukocytes (199), but also by mast cells (200) , mesangial cells (201) , smooth muscle cells (202) , thyroid follicle cells (203) , and the ova of some species upon fertilization (204) . Quantitatively, the contribution of macrophages to a given pool of product varies from major (serum lysozyme) to minor Inhibition of cell Reactive oxygen intermediates, TNF-a, IL-l-a, proliferation IL-lI-,, transforming growth factor-a, interferons-a, interferon-'y, oxidized soluble immune response suppressor, CSF-G/M (action on leukemic cells), arginase; PGE2, thymidine, reactive nitrogen intermediates? (speculative)
Promotion of cell TNF-a, IL-I-a, IL-I-fl, fibroblast growth factors, proliferation platelet-derived growth factor, CSF-G/M, erythropoietin, erythroid colony-stimulating factor, plasmacytoma growth factor, leukotriene B4 (for keratinocytes) Chemotactic Leukotrienes B4 and C, IL-I-a, IL-1-fl, plateletattraction derived growth factor, platelet-activating factor, Bl-endorphin, -y-induced protein 10? (speculative) (194) , fragments of fibronectin and elastin Induction of fever IL-I-a, IL-I-a, TNF-a, interferons-a, interferon-'y (serum complement). However, quantities alone say little about the physiologic importance of secretion of a given product by macrophages, relative to its secretion by other cells.
For example, the presence of macrophages at foci ofinflammation magnifies the importance of their contribution of C2. C2 is probably rate limiting in complement fixation at extravascular sites in the early phases of inflammation, before transudate becomes exudate (205) . Minute quantities ofmacrophagederived C3 may be responsible for opsonizing yeasts (206) and leishmania (207) so that they bind better to macrophages and acquire the capacity to trigger a respiratory burst in neighboring neutrophils (208) .
As noted by Shimokado et al. (16) , many cells secrete mitogenic proteins resembling platelet-derived growth factor. Other than platelets, however, monocytes are the only blood cells that do so. In the earliest phases of atheroma formation, invasion by monocytes precedes adhesion ofplatelets (3) . In the later phases, macrophages are embedded in the intima, in direct contact with myocytes and fibrocytes. In contrast, the platelet thrombus caps the plaque at a greater distance from these target cells in a swiftflowing stream that may dilute and wash away platelet products. In other conditions that eventuate in fibrosis, platelets are virtually absent and macrophages abundant (16) . Thus, although platelets outnumber macrophages by about a hundredfold, macrophages are likely to be an important source of plateletderived growth factor (16) .
Product interactions
Another source of complexity in the macrophage secretory repertoire is the propensity of the products to affect each other. Only four of many types of interaction will be illustrated.
First, the products may affect each other's release. For example, TNF enhances macrophage capacity to release reactive oxygen intermediates (1 17) , which share antitumor activity with TNF (198) . Another cytokine whose antiproliferative action synergizes with that of TNF, interferon-'y, enhances macrophage release of TNF (209) , and like TNF, enhances macrophage capacity to secrete reactive oxygen intermediates (210) . Leukotrienes (21 1) and C5a (212) trigger the release of IL-l, C3b the release ofPGE2 (213) , and C3a the release ofthromboxane (214) . On the other hand, macrophage-derived interferon-a can block the induction by interferon-y of macrophage H202 secretion (215) , and a-2-macroglobulin-protease complexes can also suppress superoxide release by macrophages (216).
Second, macrophage products may affect each other's actions. Examples are synergy in killing bacteria by complement components and lysozyme (217) , and in degrading matrix by elastase and plasminogen activator (218) . On the negative side, macrophage elastase can cleave a-i-protease inhibitor (219) , and macrophage-derived oxidants can inactivate it (220) . Other inhibitory factors secreted by macrophages, along with the substances whose actions they block, are plasminogen activator inhibitors (42, 43) , collagenase inhibitor (49) , and IL-I inhibitors (65) (66) (67) .
Third, the macrophage products may affect the secretion by other cells of products macrophages also make. For example, TNF stimulates endothelial cells to release IL-l (139). IL-l (106, 147, 156) and TNF (140, 151) stimulate fibroblasts to release PGE2, collagenase, and CSF-G/M, and suppress adipocyte production of lipoprotein lipase (165, 166) .
Fourth, macrophage products like TNF may induce target cells to release cytokines that mediate (142, 153) or antagonize (120, 121, 140, 141) some ofthe actions attributed to the monokines.
Next steps
To move from catalog to comprehension, we must turn in two directions. First, into the cell: How are these products actually formed? What is the import of monokines without signal sequences, bound to the plasma membrane, like IL-I? Are such agents secreted in the strict sense, shed, or released from dying cells? How are signals transduced for secretion? How do macrophages respond to higher order signals that regulate secretory capacity? Second, in vivo, the really tough questions: How do macrophage secretory products actually function? Which effects are important, which figments of our assays? When do the multiple products work in concert, when in conflict? What sets the tempo? Answers will require monoclonal antibodies, complementary DNAs, recombinant proteins, transfected genes, receptor antagonists, enzyme inhibitors, and the judicious choice of animal models and human diseases for detection, deletion, and reconstitution.
